Differential expression of microRNA between triple negative breast cancer patients of African American and European American descent

2022 ◽  
pp. 1-10
Author(s):  
William M. MacCuaig ◽  
Alexandra Thomas ◽  
Juan C. Claros-Sorto ◽  
Jorge G. Gomez-Gutierrez ◽  
Adam C. Alexander ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African American ◽  
Cancer Patients ◽  
Differential Expression ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
European American ◽  
Breast Cancer Patients

scholarly journals ANXA2 expression in African American triple-negative breast cancer patients

2018 ◽  
Vol 174 (1) ◽  
pp. 113-120 ◽  
Author(s):  
Lee D. Gibbs ◽  
Pankaj Chaudhary ◽  
Kelsey Mansheim ◽  
Richard J. Hare ◽  
Rebecca A. Mantsch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African American ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Patients

scholarly journals BRI3BP expression associates with survival in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Differential Expression ◽  
Triple Negative Breast Cancer ◽  
Microarray Data ◽  
Triple Negative ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Significant Gene

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of BRI3 binding protein, encoded by BRI3BP when comparing the primary tumors of triple negative breast cancer patients dead or alive. BRI3BP may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.

scholarly journals LGALS9C expression associates with survival in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Differential Expression ◽  
Triple Negative Breast Cancer ◽  
Microarray Data ◽  
Triple Negative ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Significant Gene

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of lectin, galactoside-binding, soluble, 9C, encoded by LGALS9C when comparing the primary tumors of triple negative breast cancer patients dead or alive. LGALS9C may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.

scholarly journals ADAM15 expression associates with survival in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Differential Expression ◽  
Triple Negative Breast Cancer ◽  
Microarray Data ◽  
Triple Negative ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Significant Gene

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of ADAM metallopeptidase domain 15, encoded by ADAM15 when comparing the primary tumors of triple negative breast cancer patients dead or alive. ADAM15 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.

Sign in / Sign up

Export Citation Format

Share Document